摘要
目的探讨普伐他丁对家兔脂肪肝肝脏 １型纤溶酶原激活物抑制物（ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉ－ｔｏｒｌ， ＰＡＩ－１） ｍＲＮＡ表达的影响。方法观察普代他丁（治疗组， ｎ＝１ ０）对高脂饮食诱发家兔高脂血症脂肪肝的形成，以及肝脏ＰＡＩ－１ ｍＲＮＡ表达及其血浆活性的影响，并设模型组（ｎ＝１０）和正常组（ｎ＝７）作对照。结果与正常组相比，模型组家兔肝脏呈重度肝细胞脂肪变性，血浆脂质和ＰＡＩ＝１活性显著增高，肝组织ＰＡＩ＝１ｍＲＮＡ呈过度表达。与模型组相比，治疗组肝组织学脂肪变性无明显改善，但血脂和ＰＡＩ－１活性显著下降，１２周时ＰＡＩ—１活性分别为（１４．０ ± ２．５） ｘ １０~－３Ｕ／Ｌ和（８．６１ ±２．０） ｘ １０~－３Ｕ／Ｌ。肝ＰＡＩ—１ｍＲＮＡ表达亦显著减少。结论普伐他丁可减少高脂血症脂肪肝家兔肝脏ＰＡＩ—１基因的过度表达，并降低其血浆ＰＡＩ－１活性。
Objective To explore the effects of Pravastatin on the changes of plasminogen activator inhibitor 1 (PAI- 1 ) gene expression of hepatic tissue in rabbit with fatty liver. Methods We observed the influences of Pravastatin on the rabbit model of hyperlipidemia and fatty liver induced by high fat diet for 12 weeks, and the plasma PAI-1 activity and the hepatic PAI-1 mRNA expression in therapeutic group(n=10); and meanwhile, designed the model group(n=10) and nor- mal group(n=7) as control. Results Severe hepatocellular steatosis was found in model group compared with normal group. Plasma lipids and PAI-1 activity increased in model group in 6 and 12 weeks, and was significantly higher than nor- mal group in 12 weeks. PAI-1 mRNA relative values in hepatic tissue in model group were higher than those in normal group. Compared with model group, hepatic pathological manifestation with the respect of steatosis had no obvious changes in therapeutic group, but the lipid content and PAI-1 activity in the plasma and the expression of PAI-1 mRNA in the liver were significantly reduced. The activity of PAI was(14.0 ±2.5) x 10^-3 U/L in model group, and(8.6 ± 2.0) x 10^-3 U/L in thera- peutic group in 12 weeks. Conclusion Pravastatin could inhibit over--expression of PAI-l mRNA in the rabbit liver with hyperlipidemia and fatty liver, and reduce its plasma PAI-1 activity.
出处
《中华肝脏病杂志》
CAS
CSCD
2000年第2期70-72,共3页
Chinese Journal of Hepatology
基金
国家自然科学基金!39800051
关键词
脂肪肝
PAI-1
基因表达
普伐他丁
MRNA
Fatty liver
Plasminogen activator inhibitor 1
Gene expression
Pravastatin
